Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check4 days agoChange DetectedUpdated study record dates: Enrollment (Actual) 13 and Study Completion (Actual) 2025-08-21, plus Last Update Posted 2025-10-01. The rest of the study details appear unchanged.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check33 days agoChange DetectedCore content and status/version information updated: old recruitment/status indicators removed; newer operating status notice and updated dates/revision added.SummaryDifference4%

- Check40 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated to v3.0.2, indicating a minor content update. The older v3.0.1 tag was removed, and the 'Back to Top' element was deleted.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check69 days agoChange DetectedThe web page has been updated to include new drug information and facility details, while some previous drug information and related topics have been removed.SummaryDifference6%

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.